After obtaining his medical degree from NYU School of Medicine, Dr. Carvajal completed his residency at the University of Michigan. As the director of Experimental Therapeutics and the Melanoma Service at Columbia, he focuses on translational research to discover new treatment modalities. Dr. Carvajal has authored numerous publications and received awards such as the American Cancer Society Physician Research Award, reflecting his commitment to advancing cancer care.
Dr. Richard Carvajal is an expert in rare melanoma subtypes, such as uveal melanoma, at Columbia University Irving Medical Center. With extensive experience in clinical trials, he has been at the forefront of developing targeted therapies and immunotherapies for melanoma patients. Dr. Carvajal’s clinical practice emphasizes personalized medicine, ensuring that each patient receives treatment tailored to their specific genetic profile.
After obtaining his medical degree from NYU School of Medicine, Dr. Carvajal completed his residency at the University of Michigan. As the director of Experimental Therapeutics and the Melanoma Service at Columbia, he focuses on translational research to discover new treatment modalities. Dr. Carvajal has authored numerous publications and received awards such as the American Cancer Society Physician Research Award, reflecting his commitment to advancing cancer care.